Compare TCPC & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TCPC | SPRY |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 346.5M | 415.7M |
| IPO Year | 2006 | 2020 |
| Metric | TCPC | SPRY |
|---|---|---|
| Price | $4.18 | $4.01 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $4.50 | ★ $22.50 |
| AVG Volume (30 Days) | 703.4K | ★ 1.4M |
| Earning Date | 11-05-2026 | 11-09-2026 |
| Dividend Yield | ★ 16.11% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $84,278,000.00 |
| Revenue This Year | N/A | $52.57 |
| Revenue Next Year | N/A | $45.52 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.08 | $3.89 |
| 52 Week High | $6.25 | $13.15 |
| Indicator | TCPC | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 59.39 | 37.26 |
| Support Level | $3.92 | N/A |
| Resistance Level | $4.24 | $4.60 |
| Average True Range (ATR) | 0.10 | 0.27 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 78.67 | 16.35 |
BlackRock TCP Capital Corp is an externally-managed specialty finance company focused on middle-market lending. Its investment objective is to achieve high total returns through current income and capital appreciation, with an emphasis on principal protection. It seeks to achieve its investment objective through investments in debt securities of middle-market companies. The group generates returns through a combination of the receipt of contractual interest payments on debt investments and origination and similar fees, and, to a lesser extent, equity appreciation through options, warrants, conversion rights, or direct equity investments.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.